|
To,
The Members
Boston Commerce Limited
(Formerly known as Boston Bio Systems Limited)
Your directors have great pleasure in presenting the Annual Report together with the
Audited Accounts of the Company for the year ended at 31st March, 2026.
FINANCIAL SUMMARY AND HIGHLIGHTS
The Company's financial performance for the year under review along with previous
years' figures is given hereunder:
(Amount in lakhs)
Particulars |
For Financial Year Ended |
|
March 31, 2026 |
March 31, 2025 |
Total Income |
48.37 |
19.25 |
Total Expenditure |
765.98 |
73.98 |
Profit after Depreciation but before Tax |
(717.61) |
(54.73) |
| Less: Current Tax |
0.00 |
0.00 |
| Less: Deferred Tax |
0.00 |
0.00 |
Profit / (Loss) After Tax |
(717.61) |
(54.73) |
Financial Year 2025-26 was a challenging year for the Company. Despite the financial
performance during the year, the Company continued to focus on strengthening its
operations, governance and compliance framework and evaluating opportunities for
sustainable growth in the future.
STATE OF COMPANIES AFFAIR AND FUTURE OUTLOOK
During the financial year 2025-26, the Company continued to carry on its business
activities and evaluate opportunities for strengthening its operations and improving its
overall business prospects. The Company reported a loss of 717.61 lakhs for the year under
review, as compared to a loss of 54.73 lakhs in the previous financial year 2024-25.
The financial performance during the year reflects the challenging operating
environment and the impact of higher expenditure and other factors affecting the Company's
operations. The Board and management continue to focus on improving operational
efficiency, exercising prudent financial management and strengthening the Company's
internal processes, governance and compliance framework.
During the year, the Members also approved the alteration of the Object Clause of the
Memorandum of Association, thereby enabling the Company to evaluate business opportunities
in additional areas, including information technology and software services, agriculture
and allied activities, real estate development, trading, e-commerce and other allied
activities. Any new business activity will be undertaken after due consideration of its
commercial viability, financial implications, associated risks and applicable regulatory
requirements.
The Board remains focused on stabilising the Company's financial position, improving
its operating performance and identifying suitable opportunities that may contribute to
sustainable growth and long-term value creation for stakeholders.
For a detailed discussion on the Company's performance, industry environment,
opportunities, risks and future outlook, reference may be made to the Management
Discussion and Analysis Report forming part of this Annual Report.
DIVIDEND
During the reporting period, in order to conserve the resources of the Company for
future growth and development, the Board of Directors do not recommend any dividend.
TRANSFER TO RESERVES
During the period under review, no amount was transferred to General Reserve of the
Company.
CHANGE IN NATURE OF BUSINESS
During the year under review, there was no material change in the nature of the
business actually carried on by the Company. However, the Members of the Company approved
the alteration of the Object Clause of the Memorandum of Association to broaden the scope
of activities that may be undertaken by the Company, including activities relating to
information technology and software services, agriculture and allied activities, real
estate development, trading, e-commerce and other allied activities. The alteration
enables the Company to explore and undertake such business activities as and when
considered commercially appropriate, subject to applicable laws and regulatory approvals.
CHANGE IN NAME OF THE COMPANY
During the year under review, the name of the Company was changed from Boston Bio
Systems Limited to Boston Commerce Limited.
The Registrar of Companies, Ministry of Corporate Affairs, approved the change of name
and issued a fresh Certificate of Incorporation pursuant to change of name on 27th
November, 2025. Thereafter, the approval of BSE Limited in respect of the change of name
became effective from 20th February, 2026.
Accordingly, with effect from the aforesaid approvals, the Company is known as Boston
Commerce Limited (Formerly known as Boston Bio Systems Limited).
ALTERATION OF MEMORANDUM AND ARTICLES OF ASSOCIATION
During the year under review, the Members of the Company, at the 30th Annual General
Meeting, approved the alteration of the Object Clause of the Memorandum of Association of
the Company pursuant to the applicable provisions of the Companies Act, 2013, inter alia,
to enable the Company to undertake additional business activities relating to information
technology and software services, agriculture and allied activities, real estate
development, trading, e-commerce and other allied activities.
Further, the Members approved the adoption of a new set of Memorandum of Association of
the Company in conformity with the provisions of the Companies Act, 2013, in substitution
of the existing Memorandum of Association framed under the Companies Act, 1956.
The Members also approved the adoption of a new set of Articles of Association of the
Company in conformity with the provisions of the Companies Act, 2013, in substitution and
exclusion of the existing Articles of Association of the Company.
The necessary filings in respect of the aforesaid alterations were made with the
Registrar of Companies in accordance with the applicable provisions of the Companies Act,
2013 and the rules made thereunder.
TRANSFER OF AMOUNTS TO INVESTOR EDUCATION AND PROTECTION FUND
The Company does not have any funds lying unpaid or unclaimed for a period of seven
years. Therefore, no funds were required to be transferred to Investor Education and
Protection Fund.
CASH FLOW AND FINANCIAL STATEMENTS
As required under Regulation 34 of the Listing Regulations, a Cash Flow Statement and
Financial Statement form part of the Annual Report.
SHARE CAPITAL
- Authorized Capital
During the year reporting period, the Authorized Share Capital of your Company as on
31st March 2026 stood at Rs. 8,00,00,000/- (Rupees Eight Crores) divided into 80,00,000
Equity Shares of Rs. 10/- each.
- Issued, Subscribed and Paid-up Share Capital
The Issued, Subscribed and Paid-up Share Capital as on 31st March, 2026 was Rs.
7,00,22,000 (Rupees Seven Crores Twenty-Two Thousand) divided into 70,02,200 Equity Shares
of 10/- each. During the reporting period, there is no change in the share capital of the
company.
DETAILS OF SUBSIDIARIES, JOINT VENTURES OR ASSOCIATE COMPANIES DURING THE YEAR
During the reporting period, the company does not have any holding company or
subsidiary company or joint venture.
MATERIAL CHANGES AND COMMITMENTS, IF ANY, AFFECTING THE FINANCIAL POSITION OF THE
COMPANY WHICH HAVE OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR OF THE COMPANY TO WHICH
THE FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT
There have been no material changes and commitments affecting the financial position of
the Company which have occurred between the end of the financial year ended 31st March,
2026 and the date of this Report.
The Company has continued to carry on its business activities in the ordinary course
and has taken necessary steps from time to time to strengthen its management, governance
and regulatory compliance framework. The changes in the composition of the Board of
Directors and Key Managerial Personnel subsequent to the close of the financial year have
been appropriately disclosed elsewhere in this Report.
Except for the matters disclosed in this Report, wherever applicable, no event or
commitment has occurred subsequent to 31st March, 2026 and up to the date of this Report
which has a material impact on the financial position of the Company.
SECRETARIAL STANDARD
The Directors state that applicable Secretarial Standards i.e. SS-1 and SS-2, relating
to 'Meetings of the Board of Directors' and 'General Meetings' respectively, have been
duly followed by the Company.
DEPOSITS
The Company has not accepted deposit from the public falling within the ambit of
Section 73 of the Companies Act, 2013 and The Companies (Acceptance of Deposits) Rules,
2014. No amount of principal or interest was outstanding as on the date of Balance Sheet.
DIRECTORS AND KEY MANAGERIAL PERSONNEL
- Composition
During the year under review, the composition of the Board of Directors of the Company
underwent various changes on account of appointments, resignations and re-designations of
Directors. The composition of the Board was maintained in accordance with the applicable
provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015, as applicable.
None of the Directors or Key Managerial Personnel of the Company is disqualified under
the applicable provisions of the Companies Act, 2013 and the SEBI Listing Regulations.
Following are the details of Directors and Key Managerial Personnel (KMP) of the
Company as on 31st March, 2026:
DIN/PAN |
Name of the Director |
Designation |
Date of Appointment |
Date of Resignation |
03343352 |
Ghanshyam Dhananjay Gavali |
Managing Director |
12/02/2024 |
12/08/2026* |
10530036 |
Yash Arun Chaudhary |
Non-Executive Non- Independent Director |
12/05/2025 |
NA |
07531342 |
Aashish Shrirang Dharmadhikari |
Independent Director |
29/01/2024 |
12/05/2026* |
10469283 |
Swati Suresh Dhadve |
Independent Director |
29/01/2024 |
12/05/2026* |
CFNPR3855L |
Kunjan Nathabhai Rathod |
Chief Financial Officer |
12/05/2025 |
12/08/2026* |
| AUJPY3287G |
Nisha Yadav |
Company Secretary |
13/10/2025 |
14/07/2026* |
Changes in Board Composition
During the year under review and subsequent to the close of the financial year up to
the date of this Report, the following changes took place in the composition of the Board
of Directors and Key Managerial Personnel of the Company:
During the Financial Year 2025-26:
1. Mr. Pratik Satish Patil (DIN: 08975756) resigned from the position of Managing
Director of the Company with effect from 12th May, 2025.
2. Ms. Seema Baghel (DIN: 08209102) resigned from the position of Additional Director
of the Company with effect from 12th May, 2025.
3. Ms. Sadhana Satish Patil (DIN: 09748130) resigned from the position of Director of
the Company with effect from 12th May, 2025.
4. Ms. Manpreet Doad Powani resigned from the position of Chief Financial Officer of
the Company with effect from 12th May, 2025.
5. Mr. Ghanshyam Dhananjay Gavali (DIN: 03343352) was re-designated from Non-Executive
Independent Director to Executive Director of the Company with effect from 12th May, 2025.
6. Mr. Vishnubhai Desai was appointed as an Additional Director in the capacity of
Managing Director of the Company with effect from 12th May, 2025.
7. Mr. Yash Arun Chaudhary (DIN: 10530036) was appointed as an Additional Director in
the category of Non-Executive Non-Independent Director of the Company with effect from
12th May, 2025, and his appointment was subsequently regularised by the Members of
the Company at the Annual General Meeting held during the Financial Year 2025-26.
8. Mr. Kunjan Nathabhai Rathod was appointed as the Chief Financial Officer of the
Company with effect from 12th May, 2025.
9. Mr. Vishnubhai Mohanbhai Desai resigned from the position of Managing Director of
the Company with effect from 08th July, 2025. 10. Mr. Ghanshyam Dhananjay Gavali (DIN:
03343352) was re-designated from Executive Director to
Managing Director of the Company with effect from 08th July, 2025.
11. Ms. Mandeep Kaur resigned from the position of Company Secretary of the Company
with effect from 13th October, 2025. 12. Ms. Nisha Yadav (Membership No. A63480) was
appointed as Company Secretary of the Company with effect from 13th October, 2025.
After the close of the Financial Year 2025-26 and up to the date of this Report:
13. Mr. Aashish Shrirang Dharmadhikari resigned from the position of Independent
Director of the
Company with effect from 12th May, 2026.
14. Ms. Swati Suresh Dhadve resigned from the position of Independent Director of the
Company with effect from 12th May, 2026. 15. Ms. Jansi Patel (DIN: 11705723) was appointed
as an Additional Director in the category of Non-
Executive Independent Director of the Company with effect from 12th May, 2026, and her
appointment as an Independent Director was subsequently approved by the Members at the
ExtraOrdinary General Meeting held on 5th August, 2026. 16. Ms. Gunjan Jyotishbhai Leuva
(DIN: 11705839) was appointed as an Additional Director in the category of Non-Executive
Independent Director of the Company with effect from 12th May, 2026, and her appointment
as an Independent Director was subsequently approved by the Members at the Extra-Ordinary
General Meeting held on 5th August, 2026. 17. CS Deshna Jain (Membership No. A79463) was
appointed as the Company Secretary and Compliance
Officer of the Company with effect from 7th July, 2026.
18. Ms. Nisha Yadav resigned from the position of Company Secretary of the Company with
effect from
14th July, 2026.
19. Mr. Ghanshyam Dhananjay Gavali (DIN: 03343352) resigned from the positions of
Managing Director and Director of the Company with effect from 12th August, 2026. 20. Mr.
Kunjan Nathabhai Rathod resigned from the position of Chief Financial Officer of the
Company with effect from 12th August, 2026. 21. Mrs. Archana Chaitanya Pandya (DIN:
10147795) was appointed as an Additional Director in the capacity of Whole-Time Director
and Chief Financial Officer of the Company with effect from 14th August, 2026.
The Company has received the requisite consents, declarations and disclosures from the
Directors, wherever applicable, pursuant to the provisions of the Companies Act, 2013 and
the rules made thereunder.
DIRECTORS' RESPONSIBILITY STATEMENT
Pursuant to the provisions contained in Section 134 (5) of the Companies Act, 2013,
Your Directors, confirm that:
i) In the preparation of the annual accounts for the financial year ended on March 31,
2026 the applicable Indian Accounting Standards have been followed and there are no
material departures from the same;
ii) The selected accounting policies were applied consistently and the Directors made
judgments and estimates that are reasonable and prudent so as to give a true and fair view
of the state of affairs of the Company as at March 31, 2026 and of the loss of the Company
for the year ended on that date.
iii) Proper and sufficient care has been taken for the maintenance of adequate
accounting records in accordance with the provisions of the Companies Act, 2013 for
safeguarding the assets of the company and for preventing and detecting fraud and other
irregularities;
iv) The annual accounts have been prepared on a 'going concern' basis.
v) The Internal financial controls have been laid by the Directors to be followed by
the Company and such financial controls are adequate and were operating effectively.
vi) Proper systems had been devised in compliance with the provision of the
all-applicable laws and such systems were adequate and operating effectively.
EXTRACT OF ANNUAL RETURN
Pursuant to the provisions of 92(3) and Section 134(3) (a) of the Companies, Act,2013
read with Rule 12 of the Companies (Management and Administration) Rules, 2014, the draft
Annual Return of the Company for the Financial Year 31st March, 2026 is uploaded on the
website of the Company and can be accessed at http://www.bostonbio.in.
CORPORATE GOVERNANCE REPORT
As per Regulation 15 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, the
Corporate Governance provisions as specified in Regulation 17 to 27, clauses (b) to (i)
[and (t)] of sub-regulation (2) of regulation 46 and Paragraph C, D and E of Schedule V
are not applicable on the companies whose paid- up share capital and net worth is less
than Rupees Ten Crore and Rupees Twenty-Five Crore respectively.
Since the paid-up share capital and net worth of the Company is less than the aforesaid
threshold limit, the Company is not required to comply with the above mentioned Corporate
Governance provisions.
DETAILS OF THE BOARD MEETINGS HELD DURING THE YEAR 1ST APRIL, 2025 TO 31st March, 2026
The details of the meetings of the Board of Directors held during the financial year
2025-26 and the attendance of each Director of Boston Commerce Limited (Formerly known as
Boston Bio Systems Limited) thereat are set out below:
Date |
Pratik Satish Patil |
Sadhana Satish Patil |
Ghanshyam Dhananjay Gavali |
Aashish Shrirang Dharmadhikari |
Swati Suresh Dhadve |
Seema Baghel* |
Yash Arun Chaudhary |
Vishnubhai Desai |
| 12/05/2025 |
Present |
Present |
Present |
Present |
Present |
Present |
Present |
Present |
| 30/05/2025 |
NA |
NA |
Present |
Present |
Present |
NA |
Present |
Present |
| 08/07/2025 |
NA |
NA |
Present |
Present |
Present |
NA |
Present |
Present |
| 14/08/2025 |
NA |
NA |
Present |
Present |
Present |
NA |
Present |
NA |
| 04/09/2025 |
NA |
NA |
Present |
Present |
Present |
NA |
Present |
NA |
| 13/10/2025 |
NA |
NA |
Present |
Present |
Present |
NA |
Present |
NA |
| 14/11/2025 |
NA |
NA |
Present |
Present |
Present |
NA |
Present |
NA |
| 13/02/2026 |
NA |
NA |
Present |
Present |
Present |
NA |
Present |
NA |
SEPARATE MEETING OF INDEPENDENT DIRECTORS
Independent Directors of the Company held their Separate meeting under Regulation 25(3)
of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Schedule
IV of Companies Act, 2013 on 30th May, 2025 at the registered office of the
Company.
DIRECTORS RETIRING BY ROTATION
Pursuant to Section 152(6) of the Companies Act, 2013, unless the Articles of
Association of the Company provide for the retirement of all Directors at every Annual
General Meeting, not less than two-thirds of the total number of Directors of a public
company shall be persons whose period of office is liable to determination by retirement
by rotation. Further, one-third of such Directors, or the number nearest to one-third,
shall retire from office at every Annual General Meeting.
During the year under review and subsequent to the close of the financial year, there
were changes in the composition of the Board. Mr. Ghanshyam Dhananjay Gavali (DIN:
03343352) resigned from the office of Managing Director and Director of the Company with
effect from 12th August, 2026.
Accordingly, having regard to the composition of the Board as on the date of this
Report and the provisions of Section 152(6) of the Companies Act, 2013, Mr. Yash Arun
Chaudhary (DIN: 10530036), Non-Executive Non-Independent Director of the Company, is
liable to retire by rotation at the ensuing Annual General Meeting and, being eligible,
has offered himself for re-appointment.
INDEPENDENT DIRECTORS DECLARATION
The Company has received the Declaration of Independence from its Independent Directors
confirming that they meet the criteria of independence as provided in section 149(6) of
the Companies Act, 2013 read with Regulations 16 of SEBI (Listing Obligations &
Disclosure Requirements) Regulations, 2015 and that they are not disqualified from
continuing their appointment as Independent Director.
During the year under review the non- executive directors of the company had no
Pecuniary relationship or transactions with the Company other than sitting fees,
commission, if any and reimbursement of expenses incurred for the purpose of attending the
meetings of the board or committees of the company.
The Company has received requisite annual declarations/confirmations from all the
aforesaid Independent Directors. The Board of Directors of the Company is of the view that
Independent Directors fulfill the criteria of independence and they are independent from
the management of the Company.
The Company has noted that the names of all Independent Directors have been included in
the data bank maintained with the Indian Institute of Corporate Affairs, Manesar ('IICA').
Accordingly, all the Independent
Directors of the Company have registered themselves with IICA for the said purpose. In
terms of Section 150 of the Act read with the Companies (Appointment & Qualification
of Directors) Rules, 2014, as amended thereof, both the Independent Directors are exempted
from undertaking online proficiency self-assessment test conducted by the IICA.
DISCLOSURE ON THE NOMINATION AND REMUNERATION POLICY OF THE COMPANY PURSUANT TO SECTION
134(3) (e) AND SECTION 178 (3)
The Company's Policy on Director's appointment and remuneration including criteria for
determining qualifications, positive attributes, independence of a Director and other
matters as provided under Section
178(3) of the Companies Act, 2013 can be accessed on the Company's website at
http://www.bostonbio.in.
The Objective of the Policy is to ensure that
- The level and composition of remuneration is reasonable and sufficient to attract,
retain and motivate Directors of the quality required to run the Company successfully. -
Relationship of remuneration to performance is clear and meets appropriate performance
benchmarks and - Remuneration to Directors, Key Managerial Personnel and Senior Management
involves a balance between fixed and incentive pay reflecting short and long term
performance objectives appropriate to the working of the Company and its goals.
DETAILS OF ESTABLISHMENT OF VIGIL MECHANISM
Pursuant to the provisions of Section 177(9) of the Companies Act, 2013 read with the
Companies (Meetings of Board and its Powers) Rules, 2014, the Company has formulated a
'Whistle Blower Policy' for the Directors and Employees to report genuine concerns or
grievances about unethical behavior, actual or suspected fraud or violation of the
Company's Code of Conduct and provides safeguard against victimization of director or
employees or any other person who avail the mechanism and also provide for direct access
to the Chairman of the Audit Committee in exceptional cases. The same is also uploaded on
the website of the Company at http://www.bostonbio.in.
During the year under review, no complaints have been received by the Company from any
whistle blower.
MANAGEMENT DISCUSSION AND ANALYSIS REPORT
The Management Discussion and Analysis Report for the Financial Year 2025-26 as
required under Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015 is annexed to this Report as Annexure - I.
DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS UNDER SUB-SECTION (12) OF SECTION 143
OTHER THAN THOSE WHICH ARE REPORTABLE TO THE CENTRAL GOVERNMENT
During the year under consideration, Statutory Auditor has not reported any instances
of frauds committed in the Company under section 143(12) of the Companies Act, 2013.
HUMAN RESOURCES
The Management has a healthy relationship with the officers and the Employee.
17. AUDITORS &THEIR REPORT
- Statutory Auditors
Pursuant to the provisions of Section 139 and other applicable provisions, if any, of
the Companies Act, 2013 and the rules made thereunder, M/s Nahar V & Company,
Chartered Accountants (Firm Registration No. 010443C), were appointed as the Statutory
Auditors of the Company. During the financial year under review, M/s Nahar V & Company
tendered their resignation from the office of Statutory Auditors of the Company with
effect from 4th September, 2025, resulting in a casual vacancy in the office of the
Statutory Auditors. Pursuant to the provisions of Section 139(8) of the Companies Act,
2013, the Board of Directors appointed M/s Sunit M Chhatbar & Company, Chartered
Accountants (Firm Registration No. 141068W), as the Statutory Auditors of the Company on
4th September, 2025, to fill the casual vacancy caused by the resignation of M/s Nahar V
& Company, subject to the approval of the Members of the Company in accordance with
the applicable provisions of the Act.
M/s Sunit M Chhatbar & Company, Chartered Accountants, have audited the financial
statements of the Company for the financial year ended 31st March, 2026. The Statutory
Auditors' Report on the financial statements of the Company for the financial year ended
31st March, 2026 forms part of the Annual Report. The observations, qualifications,
reservations or adverse remarks, if any, made by the Statutory Auditors in their Report
and the Board's explanations or comments thereon are dealt with separately in this Report,
wherever applicable.
- Secretarial Audit
In terms of the provisions of Section 204 of the Companies Act, 2013 ("the
Act") read with Rule 9 of the Companies
(Appointment and Remuneration of Managerial Personnel) Rules, 2014, M/s Shashank Kumar
& Associates, Peer Reviewed Practising Company Secretaries, were appointed as the
Secretarial Auditor of the Company for the financial year 2025-26.
M/s Shashank Kumar & Associates conducted the Secretarial Audit of the Company for
the financial year ended 31st March, 2026. The Secretarial Audit Report in Form MR-3 is
annexed to this Report as Annexure-II and forms an integral part of the Directors' Report.
The Secretarial Audit Report does not contain any qualification, reservation, adverse
remark or disclaimer. The Secretarial Auditor has, however, observed that there is scope
for further strengthening the systems and processes of the Company for monitoring and
ensuring compliance with applicable laws, rules, regulations and guidelines. The Board has
taken note of the said observation and continues to take appropriate steps to strengthen
the Company's compliance monitoring, internal processes and corporate governance
framework.
Subsequent to the close of the financial year, the Board of Directors, at its meeting
held on 11th September, 2026, considered and recommended the appointment of CS Mehul
Raval, Company Secretary in Whole-time Practice (Membership No. A28155 and Certificate of
Practice No. 10500), as the Secretarial Auditor of the Company, subject to the approval of
the Members at the ensuing Annual General Meeting. In accordance with the applicable
provisions of Section 204 of the Companies Act, 2013 and Regulation 24A of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has
recommended his appointment as the Secretarial Auditor of the Company for the FY 2026-27.
- Internal Audit
In terms of the provision of the Section 138 of the Companies Act, 2013 read with the
Rule 13 of the Companies (Accounts) Rules, 2014, the Board had appointed M/s Vyom Advisors
(Proprietorship Firm) as
Internal Auditor of the Company for the financial year 2025-2026. The Report of the
Internal Auditors is reviewed by the Audit Committee.
PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186 OF THE COMPANIES ACT,
2013
The Particulars of loans, guarantees and investments have been disclosed in the
financial statements.
PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES
During the year under review, there were no transactions held either at arm's length or
not at arm's length basis.
Accordingly, the disclosure in Form AOC-2 as prescribed under Section 134 of the
Companies Act, 2013 read with the Companies (Accounts) Rules, 2014 is not required and
hence, the same is not attached with this Report. Details of transactions with related
parties have been provided in the notes to the Financial Statements of the Company.
CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNING AND OUTGO
The Company does not have any manufacturing activity. Thus, the provisions related to
conservation of energy and technology absorption are not applicable on the Company.
However, the Company makes all efforts towards conservation of energy, protection of
environment and ensuring safety.
Further, details of foreign exchange earnings and outgo, details as mentioned below:
| Year |
Foreign Outgo |
Foreign Exchange Earning |
| 2025-26 |
NIL |
NIL |
STATEMENT CONCERNING DEVELOPMENT AND IMPLEMENTATION OF RISK MANAGEMENT POLICY OF THE
COMPANY
Pursuant to the provisions of Section 134(3)(n) of the Companies Act, 2013, the Company
has a structured Risk Management Policy duly approved by the Board of Directors. The Risk
Management process is designed to safeguard the Company from various risks through
adequate and timely actions. It is designed to anticipate, evaluate and mitigate risks in
order to minimize its impact on the business of the Company. The potential risks are
integrated with management process such that they receive the necessary consideration
during the decision making. It has been dealt in greater detail in Management Discussion
and Analysis Report annexed to this Report.
CORPORATE SOCIAL RESPONSIBILITY POLICY
Pursuant to the provisions of Section 135(1) of the Companies Act, 2013, the provisions
related to Corporate Social Responsibility (CSR) are applicable on companies having net
worth of rupees five hundred crore or more; or turnover of rupees one thousand crore or
more; or a net profit of rupees five crore or more. The present financial position of the
Company does not make it mandatory for the Company to undertake CSR initiatives or to
formulate CSR Policy during the Financial Year ended March 31, 2026. The Company will
constitute CSR Committee, develop CSR Policy and implement the CSR initiatives whenever
the same becomes applicable on the Company.
EVALUATION BY BOARD OF ITS OWN PERFORMANCE, ITS COMMITTEES AND INDIVIDUAL DIRECTORS
In compliance with the provisions of the Act, and SEBI (Listing Obligations and
Disclosure Requirements)
Regulations, 2015, the performance evaluation was carried out as under:
Board:
In accordance with the criteria suggested by the Nomination and Remuneration Committee,
the Board of Directors evaluated the performance of the Board, having regard to various
criteria such as Board composition, Board processes, Board dynamics etc. The Independent
Directors, at their separate meeting, also evaluated the performance of the Board as a
whole based on various criteria. The Board and the Independent Directors were of the view
that performance of the Board of Directors as a whole was satisfactory.
Committees of the Board:
The performance of the Audit Committee, the Nomination and Remuneration Committee, the
Stakeholders Relationship Committee was evaluated by the Board having regard to various
criteria such as committee composition, committee processes, committee dynamics etc. The
Board was of the view that all the committees were performing their functions
satisfactorily.
Individual Directors:
In accordance with the criteria suggested by the Nomination and Remuneration Committee,
the performance of each director was evaluated by the entire Board of Directors (excluding
the director being evaluated) on various parameters.
Independent Directors, at their separate meeting, have evaluated the performance of Non
independent Directors and the Board as a whole; and of the Chairman of the Board, taking
into account the views of other Directors; and assessed the quality, quantity and
timeliness of flow of information between the Company's
Management and the Board that is necessary for the Board to effectively and reasonably
perform their duties. The Board and the Independent Directors were of the view that
performance of the all the Directors as a whole was satisfactory.
The evaluation framework for assessing the performance of the Directors includes the
following broad parameters:
- Relevant expertise;
- Attendance of Directors in various meetings of the Board and its Committees;-
Effective participation in decision making process;- Objectivity and independence;
- Level of awareness and understanding of the Company's business;
- Professional conduct of the directors in various meetings of the Board and its
committees;- Compliance with the Code of Conduct of the Company;- Ability to act in the
best interest of the Company
INTERNAL FINANCIAL CONTROLS
The Company has laid proper and adequate systems of internal financial control
commensurate with the size of its business and nature of its operations with regard to the
following:
(i) Systems have been laid to ensure that all transactions are executed in accordance
with management's general and specific authorization. (ii) Systems and procedures exist to
ensure that all transactions are recorded as necessary to permit preparation of financial
statements in conformity with generally accepted accounting principles or any other
criteria applicable to such statements, and to maintain accountability for aspects and the
timely preparation of reliable financial information.
(iii) Access to assets is permitted only in accordance with management's general and
specific authorization. No assets of the Company are allowed to be used for personal
purposes, except in accordance with terms of employment or except as specifically
permitted. (iv) The existing assets of the Company are verified/ checked at reasonable
intervals and appropriate action is taken with respect to any differences, if any. (v)
Proper systems are in place for prevention and detection of frauds and errors and for
ensuring adherence to the Company's policies.
The Company has in place adequate internal financial controls with reference to
financial statements. During the year, such controls were tested and no reportable
material weaknesses in the design or operation were observed.
COMMITTEES OF BOARD
A. AUDIT COMMITTEE
The Audit Committee of the Board as on 31-03-2026 consist of three (3) Directors of the
company. The Audit Committee has been authorized to look after the following major
functions:
i. To recommend for appointment, remuneration and terms of appointment of auditors of
the company; ii. To review and monitor the auditor's independence and performance, and
effectiveness of audit process; iii. To examine the financial statement and the auditors'
report thereon; iv. To approve or any subsequent modification of transactions of the
company with related parties; v. To conduct scrutiny of inter-corporate loans and
investments; vi. To evaluate undertakings or assets of the company, wherever it is
necessary; vii. To evaluate internal financial controls and risk management systems; viii.
To monitor the end use of funds raised through public offers and related matters. ix. To
call for the comments of the auditors about internal control systems, the scope of audit,
including the observations of the auditors and review of financial statement before their
submission to the Board and to discuss any related issues with the internal and statutory
auditors and the management of the company. x. To investigate into any matter in relation
to the items specified in or referred to it by the Board and for this purpose shall have
power to obtain professional advice from external sources and have full access to
information contained in the records of the company.
DETAILS OF COMPOSITION, NAMES OF MEMBERS, NUMBER OF MEETINGS HELD AND ATTENDANCE OF
AUDIT COMMITTEE DURING THE YEAR FROM 01ST APRIL, 2025 TO 31st March, 2026
During the financial year 2025-2026 Five (5) Meetings of Audit Committee were held:
- 30.05.2025 - 14.08.2025 - 04.09.2025 - 14.11.2025 - 13.02.2026
Name |
Designation |
No. of meeting(s) attended |
| Aashish Shrirang |
Chairman, Independent |
5 |
| Dharmadhikari |
Director |
|
| Swati Suresh Dhadve |
Member, Independent Director |
5 |
| Ghanshyam Dhananjay Gavali |
Member, Managing Director |
5 |
B. NOMINATION AND REMUNERATION COMMITTEE
The Nomination & Remuneration Committee of the Board was formed in compliance with
provisions of Section 178 of Companies Act, 2013 and Rule 6 and 7 of Companies (Meetings
of Board and its Powers) Rules, 2014. The Committee has been authorized to look after
following major functions:
1. To identify persons who are qualified to become directors and who may be appointed
in senior management in accordance with the criteria laid down, recommend to the Board
their appointment and removal and shall carry out evaluation of every director's
performance.
2. To formulate the criteria for determining qualifications, positive attributes and
independence of a director and recommend to the Board a policy, relating to the
remuneration for the directors, key managerial personnel and other employees.
2. To ensure that
(a) the level and composition of remuneration is reasonable and sufficient to attract,
retain and motivate directors of the quality required to run the company successfully; (b)
relationship of remuneration to performance is clear and meets appropriate performance
benchmarks; and (c) remuneration to directors, key managerial personnel and senior
management involves a balance between fixed and incentive pay reflecting short and
long-term performance objectives appropriate to the working of the company and its goals.
(d) The policy so framed by the said Committee shall be disclosed in Board's Report to
shareholders.
DETAILS OF COMPOSITION, NAMES OF MEMBERS, NO. OF MEETINGS HELD AND ATTENDANCE OF
NOMINATION & REMUNERATION COMMITTEE DURING THE YEAR 1ST APRIL, 2025 TO 31st March,
2026
During the financial year 2025-2026 Three (3) meeting of Nomination & Remuneration
Committee were held:
- 12.05.2025 - 08.07.2025 - 13.10.2025
Name |
Designation |
No. of meeting(s) attended |
Swati Suresh Dhadve |
Chairperson, Independent Director |
3 |
| Aashish Shrirang Dharmadhikari |
Member, Independent Director |
3 |
| Yash Arun Chaudhary |
Member, Non-Executive Director |
3 |
C. STAKEHOLDERS RELATIONSHIP COMMITTEE
The Stakeholders Relationship Committee (SRC) is a key committee under the Companies
Act, 2013, primarily responsible for addressing the grievances and concerns of a company's
shareholders and other stakeholders.
Resolving Shareholders' / Investors' Grievances
1. Key Functions of the Stakeholders Relationship Committee:
2. Handling and resolving complaints related to:
3. Transfer/transmission of shares
4. Non-receipt of dividends
5. Non-receipt of annual reports
6. Dematerialization/rematerialization of shares
7. Any other grievance related to shares or debentures and many more.
Investor Grievances
During the financial year 2025-26, the Company received one investor complaint through
the SEBI Complaints
Redress System ("SCORES"), which was duly addressed and resolved. No investor
complaint remained pending as on
31st March, 2026.
DETAILS OF COMPOSITION, NAMES OF MEMBERS, NO. OF MEETINGS HELD AND ATTENDANCE OF
STAKEHOLDER RELATIONSHIP COMMITTEE DURING THE YEAR 1ST APRIL, 2025 TO 31st March, 2026
During the financial year 2025-2026 One (1) meeting of Stakeholder Relationship
Committee were held:
- 30.05.2025
Name |
Designation |
No. of meeting(s) attended |
| Aashish Shrirang Dharmadhikari |
Chairperson, Independent |
1 |
|
Director |
|
| Swati Suresh Dhadve |
Member, Independent Director |
1 |
| Ghanshyam Dhananjay Gavali |
Member, Managing Director |
1 |
DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION
AND REDRESSAL) ACT, 2013
The Company has in place a policy for the prevention of sexual harassment in line with
the requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition
and Redressal) Act, 2013 ("POSH Act, 2013"). Internal committees have been set
up to redress complaints received regarding sexual harassment. All employees (permanent,
contractual, temporary, trainees) are covered under this policy. During the reporting
period, there were no cases filed pursuant to the Sexual Harassment of Women at Workplace
(Prevention, Prohibition and Redressal) Act, 2013.
Number of complaints of sexual harassment received in the year |
NIL |
| Number of complaints disposed off during the year |
NIL |
| Number of cases pending for more than ninety days |
NIL |
POLICY FOR PREVENTION OF INSIDER TRADING
Pursuant to the provisions of the Securities and Exchange Board of India (Prohibition
of Insider Trading) Regulations, 2015, as amended, the Company has formulated and adopted
a Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive
Information in accordance with Regulation 8 of the said Regulations.
The Code lays down the principles and procedures to be followed for fair disclosure of
unpublished price sensitive information and is available on the website of the Company at
https://bostonbio.in.
Further, pursuant to Regulation 9 of the SEBI (Prohibition of Insider Trading)
Regulations, 2015, as amended, the Company has formulated and adopted a Code of Conduct to
Regulate, Monitor and Report Trading by Designated Persons and their Immediate Relatives.
The Code lays down the guidelines, procedures and disclosure requirements to be followed
while dealing in the securities of the Company.
The Company Secretary of the Company has been designated as the Compliance Officer for
the purpose of administering and monitoring compliance with the said Codes and the
applicable provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015.
PARTICULARS OF EMPLOYEES PURSUANT TO THE SECTION 197 (12) OF COMPANIES ACT AND RULE
5(1), 5(2) AND 5(3) OF COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL)
RULES, 2014
The information required pursuant to Section 197 read with Rule 5 of The Companies
(Appointment and Remuneration of Managerial Personnel) Rules, 2014 and Companies
(Particulars of Employees) Rules, 1975, in respect of employees of the Company and
Directors is furnished hereunder:
S.NO. PARTICULARS |
REMARKS |
1. The ratio of the remuneration of each Director to the median
remuneration of the employees of the Company for the financial year. |
During the financial year under review, no remuneration was paid to
any Director and Key Managerial Personnel's of the Company for the financial year 2025-26. |
2 The percentage increase in remuneration of each Director, Chief
Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the
financial year. |
|
3 The percentage increase in the median remuneration of employees in
the financial year. |
|
4 Average percentile increase already made in the salaries of
employees other than the managerial personnel in the last financial year and its
comparison with the percentile increase in the managerial remuneration and justification
thereof and point out if there are any exceptional circumstances for increase in the
managerial remuneration. |
|
5 Affirmation that the remuneration is as per the remuneration policy
of the Company |
|
6 The number of Permanent employees on the Pay Rolls of the Company |
4 |
Statement of Particulars of Employees pursuant to the Section 197 (12) of Companies Act
and Rule 5(2) of Companies (Appointment and Remuneration of Managerial Personnel) Rules,
2014: a) Details of the employees employed throughout the Financial Year, was in receipt
of remuneration for that year which, in the aggregate, was not less than one crore rupees
and two lakh rupees. Nil
b) Details of the employees employed for a part of the Financial Year and was in
receipt of remuneration for any part of that year, at a rate which, in the aggregate, was
not less than eight lakh and fifty thousand rupees per month; Nil
c) If employed throughout the Financial Year or part thereof and was in receipt of
remuneration in that year which, in the aggregate, or as the case may be, at a rate which,
in the aggregate, is in excess of that drawn by the Managing Director or Whole-time
Director or Manager and holds by himself or along with his spouse and dependent children,
not less than two percent of the equity shares of the Company. Nil
DISCLOSURE PERTAINING TO MAINTENANCE OF COST RECORD PERSUANT TO SECTION 148(1) OF THE
COMPANIES ACT, 2013
The company is not required to maintain Cost Records as specified u/s 148(1) of the
Companies Act, 2013 read with the applicable rules thereon for the Financial Year 2025-26.
Hence the clause is not applicable to the Company.
RISK MANAGEMENT POLICY
Pursuant to the provisions of Section 134(3)(n) of the Companies Act, 2013, the Company
has a structured Risk Management Policy duly approved by the Board of Directors. The Risk
Management process is designed to safeguard the Company from various risks through
adequate and timely actions. It is designed to anticipate, evaluate and mitigate risks in
order to minimize its impact on the business of the Company. The potential risks are
integrated with management process such that they receive the necessary consideration
during the decision making. It has been dealt in greater detail in Management Discussion
and Analysis Report annexed to this Report.
APPLICATION/PROCEEDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016
Pursuant to rule 8(5)(xi) of the Companies (Accounts) Rules, 2014, no application has
been made nor any proceeding is pending under the Insolvency and Bankruptcy Code, 2016
during the period under review.
COMPLIANCE WITH THE MATERNITY BENEFIT ACT, 1961
The Company affirms that it is in full compliance with the provisions of the Maternity
Benefit Act, 1961, as amended from time to time. The Company is committed to fostering a
supportive and inclusive work environment, and ensures that all relevant policies and
practices are regularly reviewed and aligned with the applicable statutory requirements.
WEBSITE DISCLOSURE
The Company maintains an updated website at https://bostonbio.in, which serves as a
comprehensive resource for stakeholders, including shareholders, investors, and the
general public. The website contains important information about the Company's operations,
corporate governance policies, financial reports, statutory filings, and other relevant
details.
DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE-TIME
SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL
INSTITUTIONS ALONG WITH THE REASONS THEREOF UNDER RULE 8(5)(XII) OF THE COMPANIES
(ACCOUNTS) RULES, 2014
The details of difference between amount of the valuation done at the time of
one-time settlement and the valuation done while taking loan from the Banks or Financial
Institutions along with the reasons thereof under rule 8(5)(xii) of the Companies
(Accounts) Rules, 2014 are not applicable to the Company during the period under review.
GENERAL
Your Directors state that no disclosure or reporting is required in respect of the
following items, as there were no transactions on these items during the reporting period:
(a) Issue of Equity shares with differential rights as to dividend, voting or
otherwise.
(b) Issue of shares (including sweat equity shares and ESOS) to employees of the
Company under any scheme.
(c) The Company does not have any scheme of provision of money for the purchase of its
own shares by employees or by trustees for the benefit of employees.
ACKNOWLEDGEMENT
Your directors wish to express their grateful appreciation for the valuable support and
co-operation received from sub-brokers, business associates, vendors, bankers, financial
institutions, investors, stakeholders, registrar and share transfer agent, other business
affiliates and media.
The Board places on record its sincere appreciation towards the Company's valued
clients for the support and confidence reposed by them in the organization and the
stakeholders for their continued co-operation and support to the company and looks forward
to the continuance of this supportive relationship in future.
Your directors also place on record their deep sense of appreciation for the devoted
services of the employees during the year under review.
|